Full Text View
Tabular View
No Study Results Posted
Related Studies
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
This study has been completed.
Study NCT00052013   Information provided by Novartis
First Received: January 21, 2003   Last Updated: September 21, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Von Hippel-Lindau Disease
CNS Hemangioblastoma
Retinal Hemangioblastoma
Additional conditions recognized in this trial
Hemangioblastoma
More general conditions related to this trial
Angiomatosis
Cardiovascular Diseases
Hemangioma
Hemangioma, Capillary
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Vascular Tissue
Nervous System Diseases
Neurocutaneous Syndromes
Vascular Diseases
Interventions listed in this trial
PTK787/ZK 222584
Additional drug interventions recognized in this trial
Vatalanib
More general drug interventions related to this trial
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Sponsors listed in this trial
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services